A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of SaxendaÂ®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.